Emerging drugs for the treatment of cervical cancer

Bibliography

• Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for research on Cancer. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
   Google Scholar
• Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 2009;105:107-8
   PubMed Web of Science ®Google Scholar
• Duenas-Gonzalez A, Cetina L, Coronel J, Martinez-Banos D. Pharmacotherapy options for locally advanced and advanced cervical cancer. Drugs 2010;70:403-32
   PubMed Web of Science ®Google Scholar
• Tomljenovic L, Spinosa JP, Shaw CA. Human papilomavirus (HVP) as an option for preventing cervical malignancies: (how) effective and safe? Curr Pharm Des 2013;19:1466-87
   PubMed Web of Science ®Google Scholar
• Goodwin EC, DiMaio D. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci USA 2000;97:12513-18
   PubMed Web of Science ®Google Scholar
• Gadducci A, Sartori E, Maggino T, et al. The clinical outcome of patients with stage Ia1 and Ia2 squamous cell carcinoma of the uterine cervix: a Cooperation Task Force (CTF) study. Eur J Gynaecol Oncol 2003;24:513-16
   PubMed Web of Science ®Google Scholar
• Martin-Hirsch PL, Wood NJ. Cervical cancer. Clin Evid (Online) 2011. pii: 0818
   Google Scholar
• Plante M. Evolution in fertility-preserving options for early-stage cervical cancer: radical trachelectomy, simple trachelectomy, neoadjuvantchemotherapy. Int J Gynecol Cancer 2013;23:982-9
   PubMed Web of Science ®Google Scholar
• Maneo A, Chiari S, Bonazzi C, et al. Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer. Gynecol Oncol 2008;111:438-43
   PubMed Web of Science ®Google Scholar
• Schmeler KM, Frumovitz M, Ramirez PT. Conservative management of early stage cervical cancer: is there a role for less radical surgery? Gynecol Oncol 2011;120:321-5
   PubMed Web of Science ®Google Scholar
• Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 2012;12:CD007406
   PubMed Web of Science ®Google Scholar
• Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004;22:872-80
   PubMed Web of Science ®Google Scholar
• Peters WAIII, Liu PY, Barrett RJII, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-13
   PubMed Web of Science ®Google Scholar
• Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev 2010(1):CD008285
   PubMed Web of Science ®Google Scholar
• Thomas GM. Improved treatment for cervical cancer: concurrent chemotherapy and radiotherapy. N Engl J Med 1999;340:1198-200
   PubMed Web of Science ®Google Scholar
• Duenas-Gonzalez A, Zarba JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 2011;29:1678-85
   PubMed Web of Science ®Google Scholar
• Petrelli F, De Stefani A, Raspagliesi F, et al. Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis. Gynecol Oncol 2014;134:166-71
   PubMed Web of Science ®Google Scholar
• Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer 2003;39:2470-86
   PubMed Web of Science ®Google Scholar
• McCormack M, Kadalayil L, Hackshaw A, et al. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer 2013;108:2464-9
   PubMed Web of Science ®Google Scholar
• Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649-55
   PubMed Web of Science ®Google Scholar
• Cella D, Huang HQ, Monk BJ, et al. Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2010;119:531-7
   PubMed Web of Science ®Google Scholar
• Tewari KS, Sill MW, Long HJIII, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370:734-43
   PubMed Web of Science ®Google Scholar
• Zighelboim I, Wright JD, Gao F, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol 2013;130:64-8
   PubMed Web of Science ®Google Scholar
• Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between1980 and 2010: a systematic analysis. Lancet 2011;378:1461-84
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA Cancer J Clin 2014;64:9-29
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Surveillance, epidemiology and end results program. cancer statistics. SEER stat fact sheets: cervix uteri cáncer. Available from: http://seer.cancer.gov/statfacts/html/cervix.html
   Google Scholar
• Available from: http://www.datamonitor.com/store/Product/epidemiology_cervical_cancer_the_small_decrease_in_cervical_cancer_cases_over_the_next_decade_in_the_seven_major_markets_is_driven_by_decreasing_incidence_rates?productid=HC00202-001
   Google Scholar
• Mohar A, Frias-Mendivil M. Epidemiology of cervical cancer. Cancer Invest 2000;18:584-90
   PubMed Web of Science ®Google Scholar
• Available from: http://www.academia.edu/5143003/Cervical_Cancer_Diagnostic_Tests_Pap_Smear_Colposcopy_and_ECC_Procedures_Market_Global_Industry_Analysis_By_Test_Type_and_Age_Group_Market_Size_Share_and_Forecast_2012_-2018_Sample
   Google Scholar
• Available from: http://www.bloomberg.com/apps/news?pid=newsarchive&sid=axopZKy.7v34
   Google Scholar
• Market Research: cervical cancer market is forecast to show slow growth. Available from: http://www.sys-con.com/node/2124321
   Google Scholar
• Weinstein IB, Begemann M, Zhou P, et al. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res 1997;3:2696-702
   PubMed Web of Science ®Google Scholar
• Ojesina AI, Lichtenstein L, Freeman SS, et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014;506:371-5
   PubMed Web of Science ®Google Scholar
• FDA approved drugs for oncology. Available from: www.cancerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology
   Google Scholar
• Macville M, Schrock E, Padilla-Nash H, et al. Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping. Cancer Res 1999;59:141-50
   PubMedGoogle Scholar
• Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002;89:213-28
   PubMed Web of Science ®Google Scholar
• Munger K, Scheffner M, Huibregtse JM, et al. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv 1992;12:197-217
   PubMedGoogle Scholar
• Wise-Draper TM, Wells SI. Papillomavirus E6 and E7 proteins and their cellular targets. Front Biosci 2008;13:1003-17
   PubMed Web of Science ®Google Scholar
• Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis:roles of E6 and E7 proteins. Cancer Sci 2007;98:1505-11
   PubMed Web of Science ®Google Scholar
• Sima N, Wang W, Kong D, et al. Interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53. Apoptosis 2008;13:273-81
   PubMed Web of Science ®Google Scholar
• Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 2002;21:6041-8
   PubMed Web of Science ®Google Scholar
• Sima N, Wang S, Wang W, et al. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescencein SiHa cervical carcinoma cells. Gynecol Oncol 2007;106:299-304
   PubMed Web of Science ®Google Scholar
• Bousarghin L, Touze A, Gaud G, et al. Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs. Mol Cancer Ther 2009;8:357-65
   PubMed Web of Science ®Google Scholar
• Gu W, Putral L, Hengst K, et al. Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 andE7 oncogenes. Cancer Gene Ther 2006;13:1023-32
   PubMed Web of Science ®Google Scholar
• Putral LN, Bywater MJ, Gu W, et al. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol 2005;68:1311-19
   PubMed Web of Science ®Google Scholar
• Moon MS, Lee CJ, Um SJ, et al. Effect of BPV1 E2-mediated inhibition of E6/E7 expression in HPV16-positive cervical carcinoma cells. Gynecol Oncol 2001;80:168-75
   PubMed Web of Science ®Google Scholar
• Lea JS, Sunaga N, Sato M, et al. Silencing of HPV 18 oncoproteins with RNA interference causes growth inhibition of cervical cancer cells. Reprod Sci 2007;14:20-8
   PubMed Web of Science ®Google Scholar
• Schilder RJ, Sill MW, Lee YC, et al. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Int J Gynecol Cancer 2009;19:929-33
   PubMed Web of Science ®Google Scholar
• Nogueira-Rodrigues A, do Carmo CC, Viegas C, et al. Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer. Clin Cancer Res 2008;14:6324-9
   PubMed Web of Science ®Google Scholar
• Nogueira-Rodrigues A, Moralez G, Grazziotin R, et al. Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer. Cancer 2014;120:1187-93
   PubMed Web of Science ®Google Scholar
• Goncalves A, Fabbro M, Lhommé C, et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol 2008;108:42-6
   PubMed Web of Science ®Google Scholar
• Sharma DN, Rath GK, Julka PK, et al. Role of gefitinib in patients with recurrent or metastatic cervical carcinoma ineligible or refractory to systemic chemotherapy: first study from Asia. Int J Gynecol Cancer 2013;23:705-9
   PubMed Web of Science ®Google Scholar
• Hertlein L, Lenhard M, Kirschenhofer A, et al. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients. Arch Gynecol Obstet 2011;283:109-13
   PubMed Web of Science ®Google Scholar
• Santin AD, Sill MW, McMeekin DS, et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2011;122:495-500
   PubMed Web of Science ®Google Scholar
• Farley J, Sill MW, Birrer M, et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol 2011;121:303-8
   PubMed Web of Science ®Google Scholar
• Kurtz E, Hardy-Bessard AC, Deslandres M, et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial. Gynecol Oncol 2009;113:16-20
   PubMed Web of Science ®Google Scholar
• Moore KN, Sill MW, Miller DS, et al. A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: a gynecologic oncology group study. Gynecol Oncol 2012;127:456-61
   PubMed Web of Science ®Google Scholar
• von Knebel Doeberitz M, Gissmann L, zur-Haussen H. Growth-regulating functions of human papillomavirus early gene products in cervical cancer cells acting dominant over enhanced epidermal growth factor receptor expression. Cancer Res 1990;50:3730-6
   PubMed Web of Science ®Google Scholar
• Bellone S, Palmieri M, Gokden M, et al. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecol Oncol 2003;91:231-40
   PubMed Web of Science ®Google Scholar
• Chavez-Blanco A, Perez-Sanchez V, Gonzalez-Fierro A, et al. HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer 2004;4:59
   PubMed Web of Science ®Google Scholar
• Chen W, Li F, Mead L, et al. Human papillomavirus causes an angiogenic switch in keratinocytes which is sufficient to alter endothelial cell behavior. Virology 2007;367:168-74
   PubMed Web of Science ®Google Scholar
• Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M, et al. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 2000;19:4611-20
   PubMed Web of Science ®Google Scholar
• Schmidt B, Lee HJ, Ryeom S, Yoon SS. Combining bevacizumab with radiation or chemoradiation for solid tumors: a review of the scientific rationale, and clinical trials. Curr Angiogenes 2012;1:169-79
   Google Scholar
• Schefter T, Winter K, Kwon JS, et al. RTOG:0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locallya advanced cervical carcinoma. Int J Radiat Oncol Biol Phys 2014;88:101-5
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007;9:115-19
   PubMedGoogle Scholar
• Monk BJ, Pandite LN. Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2011;29:4845
   PubMed Web of Science ®Google Scholar
• Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growthfactor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65:4389-400
   PubMed Web of Science ®Google Scholar
• Symonds P, Gourley C, Davidson S, et al. A randomized double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo en metastatic/recurrent cervicla cancer. (CRUK GRANT REF: C1256/A11216. Ann Oncol 2014;25:(Suppl 4). 10.1093/annonc/mdu438.26
   Google Scholar
• Diaz-Padilla I, Siu LL. Brivanib alanitate for cancer. Expert Opin Investig Drugs 2011;20:577-86
   PubMed Web of Science ®Google Scholar
• Taja-Chayeb L, Chavez-Blanco A, Martinez-Tlahuel J, et al. Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer. Cancer Cell Int 2006;6:22
   PubMedGoogle Scholar
• MacKay HJ, Tinker A, Winquist E, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG trial IND.184. Gynecol Oncol 2010;116:163-7
   PubMed Web of Science ®Google Scholar
• Kim MK, Kim TJ, Sung CO, et al. High expression of mTOR is associated with radiation resistance in cervical cancer. J Gynecol Oncol 2010;21:181-5
   PubMed Web of Science ®Google Scholar
• Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol 2010;117:473-6
   PubMed Web of Science ®Google Scholar
• Tinker AV, Ellard S, Welch S, et al. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG199). Gynecol Oncol 2013;130:269-74
   PubMed Web of Science ®Google Scholar
• Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012;30:777-82
   PubMed Web of Science ®Google Scholar
• Rios J, Puhalla S. PARP inhibitors in breast cancer: BRCA and beyond. Oncology 2011;25:1014-25
   PubMed Web of Science ®Google Scholar
• Ghosh U, Bhattacharyya NP. Induction of apoptosis by the inhibitors of poly (ADP-ribose) polymerase in HeLa cells. Mol Cell Biochem 2009;320:15-23
   PubMed Web of Science ®Google Scholar
• Schneider-Stock R, Ocker M. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors. IDrugs 2007;10:557-61
   PubMed Web of Science ®Google Scholar
• Duenas-Gonzalez A, Lizano M, Candelaria M, et al. Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer 2005;4:38
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Tumolo S, Roozendaal KJ, et al. 5-aza2deoxycytidine in advanced or recurrent cancer of the uterine cervix. Eur J Cancer 1991;27:5216-17
   Google Scholar
• Pohlmann P, DiLeone LP, Cancella AI, et al. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 2002;25:496-501
   PubMed Web of Science ®Google Scholar
• Gore L, Rothenberg ML, O’Bryant CL, et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 2008;14:4517-25
   PubMed Web of Science ®Google Scholar
• Munster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007;25:1979-85
   PubMed Web of Science ®Google Scholar
• Gonzalez-Fierro A, Vasquez-Bahena D, Taja-Chayeb L, et al. Pharmacokinetics of hydralazine, an antihypertensive andDNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype. Int J Clin Pharmacol Ther 2011;49:519-24
   PubMed Web of Science ®Google Scholar
• Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 2006;6:2
   PubMed Web of Science ®Google Scholar
• De la Cruz-Hernandez E, Perez-Plasencia C, Pérez-Cárdenas E, et al. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma. Oncol Rep 2011;25:399-407
   PubMed Web of Science ®Google Scholar
• Mora-Garcia M de L, Duenas-Gonzalez A, Hernandez-Montes J, et al. Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproicacid. J Transl Med 2006;4:55
   PubMed Web of Science ®Google Scholar
• Candelaria M, Gallardo-Rincon D, Arce C, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 2007;18:1529-38
   PubMed Web of Science ®Google Scholar
• Candelaria M, Cetina L, Perez-Cardenas E, et al. Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer. Eur J Gynaecol Oncol 2010;31:386-91
   PubMed Web of Science ®Google Scholar
• Mani E, Medina LA, Isaac-Olivé K, Dueñas-González A. Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate. Eur J Gynaecol Oncol 2014;35:140-2
   PubMed Web of Science ®Google Scholar
• Coronel J, Cetina L, Pacheco I, et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol 2011;28(S1):540-6
   Google Scholar
• Schoffski P. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and others olid tumors. Anticancer Drugs 2004;15:85-106
   PubMed Web of Science ®Google Scholar
• Katsumata N, Hirai Y, Kamiura S, et al. Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer. Ann Oncol 2011;22:1353-7
   PubMed Web of Science ®Google Scholar
• Yunokawa M, Katsumata N, Yamamoto H, et al. A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer. Cancer Chemother Pharmacol 2013;71:1369-74
   PubMed Web of Science ®Google Scholar
• Look KY, Blessing JA, Michener CM, Gynecologic Oncology Group Study. Phase II evaluation of capecitabine in refractory nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer 2008;18:773-8
   PubMed Web of Science ®Google Scholar
• Lorvidhaya V, Chitapanarux I, Phromratanapongse P, et al. Phase II study of capecitabine (Ro-09-1978) in patients who have failed first line treatment for locally advanced and/or metastatic cervical cancer. Gan To Kagaku Ryoho 2010;37:1271-5
   PubMedGoogle Scholar
• Benjapibal M, Thirapakawong C, Leelaphatanadit C, et al. A pilot phase II study of capecitabine plus cisplatin in the treatment of recurrent carcinoma of the uterine cervix. Oncology 2007;72:33-8
   PubMed Web of Science ®Google Scholar
• Errihani H, M´Rabti H, Ismaili N, et al. Phase II trial of capecitabine and cisplatin in advanced, persistent, or recurrent carcinoma of the cervix. Int J Gynecol Cancer 2011;21:373-7
   PubMed Web of Science ®Google Scholar
• Goodin S. Novel cytotoxic agents: epothilones. Am J Health Syst Pharm 2008;65(10 Suppl 3):S10-15
   PubMed Web of Science ®Google Scholar
• Agrawal M, Edgerly M, Fojo T, Kotz H. Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog. Gynecol Oncol 2003;90:96-9
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002;8:641-61
   PubMed Web of Science ®Google Scholar
• Lee SW, Kim YM, Kim MB, et al. Chemosensitivity of uterine cervical cancer demonstrated by the histoculture drug response assay. Tohoku J Exp Med 2009;219:277-82
   PubMed Web of Science ®Google Scholar
• Hwang JH, Lim MC, Seo SS, et al. Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix. Jpn J Clin Oncol 2011;41:624-9
   PubMed Web of Science ®Google Scholar
• Mitsui I, Kumazawa E, Hirota Y, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 1995;86:776-82
   PubMedGoogle Scholar
• Craighead PS, Pearcey R, Stuart G. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2000;48:791-5
   PubMed Web of Science ®Google Scholar
• DiSilvestro PA, Ali S, Craighead PS, et al. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB IIIA and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group Study. J Clin Oncol 2014;32:458-64
   PubMed Web of Science ®Google Scholar
• Finch RA, Liu M, Grill SP, et al. Triapine (3-aminopyridine-2 carboxaldehyde thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 2000;59:983-91
   PubMed Web of Science ®Google Scholar
• Kunos CA, Radivoyevitch T, Pink J, et al. Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers. Radiat Res 2010;174:574-81
   PubMed Web of Science ®Google Scholar
• Kunos CA, Waggoner S, von Gruenigen V, et al. Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer. Clin Cancer Res 2010;16:1298-306
   PubMed Web of Science ®Google Scholar
• Kunos CA, Radivoyevitch T, Waggoner S, et al. Radiochemotherapy plus 3-aminopyridine-2carboxaldehyde thiosemicarbazone (3-AP, NSC # 663249) in advanced stage cervical and vaginal cancers. Gynecol Oncol 2013;130:75-80
   PubMed Web of Science ®Google Scholar
• Kunos CA, Sherertz TM. Long-term disease control with triapine-based radiochemotherapy for patients with stage IB2-IIIB cervical cancer. Front Oncol 2014;4:184
   PubMedGoogle Scholar
• Shetty N, Gupta S. Eribulin drug review. South Asian J Cancer 2014;3:57-9
   PubMedGoogle Scholar
• Yared JA, Kaczuk KH. Update on taxene development: new analogs and new formulations. Drug Des Devel Ther 2012;6:371-84
   PubMed Web of Science ®Google Scholar
• Alberts DS, Blessing JA, Landrum LM, et al. Phase II trail of nab-paclitaxel in the treatment of recurrent or persistent advanced cervical cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 2012;127:451-5
   PubMed Web of Science ®Google Scholar
• Miller DS, Blessing JA, Bodurka DC, Gynecologic Oncology Group. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2008;110:65-70
   PubMed Web of Science ®Google Scholar
• Lorusso D, Ferrandina G, Pignata S, et al. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX-1 study of the MITO (Multicentre Italian Trials in the Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol 2010;21:61-6
   PubMed Web of Science ®Google Scholar
• Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol 2009;19:97-113
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang C, Liang W. Development of RNAi technology for targeted therapy - A track of siRNA based agents to RNAi therapeutics. J Control Release 2014;193:270-81
   PubMed Web of Science ®Google Scholar
• Zhao CY, Szekely L, Bao W, Selivanova G. Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. Cancer Res 2010;70:3372-81
   PubMed Web of Science ®Google Scholar
• Mungala R, Kausar H, Munjal C, Gupta RC. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in humancervical cancer cells. Carcinogenesis 2011;32:1697-705
   PubMed Web of Science ®Google Scholar
• Allen KL, Tschantz DR, Awad KS, et al. A plant lignan, 3¢-O methylnordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cells. Mol Carcinog 2007;46:564-75
   PubMed Web of Science ®Google Scholar
• Beerheide W, Sim MM, Tan YJ, et al. Inactivation of the human papillomavirus-16 E6 oncoprotein by organic disulfides. Bioorg Med Chem 2000;8:2549-60
   PubMed Web of Science ®Google Scholar
• Baleja JD, Cherry JJ, Liu Z, et al. Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins. Antiviral Res 2006;72:49-59
   PubMed Web of Science ®Google Scholar
• Cho Y, Cho C, Joung O, et al. Development of screening systems for drugs against human papillomavirus-associated cervical cancer: based on E6-E6AP binding. Antiviral Res 2000;47:199-206
   PubMed Web of Science ®Google Scholar
• Abdulkarim B, Sabri S, Deutsch E, et al. Antiviral agent cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 2002;21:2334-46
   PubMed Web of Science ®Google Scholar
• Sirianni N, Wang J, Ferris RL. Antiviral activity of cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity. Oral Oncol 2005;41:423-8
   Google Scholar
• Yang Y, Zhao X, Chen W, et al. Effects of cidofovir on human papillomavirus-positive cervical cancer cells xenografts in nude mice. Oncol Res 2010;18:519-27
   PubMed Web of Science ®Google Scholar
• Snoeck R, Andrei G, De Clercq E. Cidofovir in the treatment of HPV-associated lesions. Verh K Acad Geneeskd Belg 2001;63:93-120
   PubMedGoogle Scholar
• Van Pachterbeke C, Becella D, Rozenber S, et al. Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. Gynecol Oncol 2009;115:69-74
   PubMed Web of Science ®Google Scholar
• Trarbach T, Moehler M, Heinemann V, et al. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1(TRAIL-R1) in patients with refractory colorectal cancer. Br J Cancer 2010;102:506-12
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Blessing JA, Rader J, et al. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Invest New Drugs 2003;21:453-7
   PubMed Web of Science ®Google Scholar
• Nezhat F, Wadler S, Muggia F. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study. Gynecol Oncol 2004;931:144-8
   Google Scholar
• Basu P, Mehta AO, Jain MM, et al. ADXS11-001 immunotherapy targeting HPV-E7: final results from a phase 2 study in Indian women with recurrent cervical cancer. J Clin Oncol 2014;32(5 Suppl):abstract 5610
   Google Scholar
• Hinrichs CS, Stevanovic S, Draper L, et al. HPV-targeted tumor-infiltrating lymphocytes for cervical cancer. J Clin Oncol 2014;32(5 Suppl):abstract LBA3008
   Google Scholar